Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS)

Archive ouverte

Ohanna, M. | Giuliano, S. | Bonet, C. | Imbert, V. | Hofman, V. | Zangari, J. | Bille, K. | Robert, Cédric, Robert | Bressac-de Paillerets, B. | Hofman, P. | Rocchi, S. | Peyron, J.-F. | Lacour, J.-P. | Ballotti, R. | Bertolotto, C.

Edité par CCSD ; Cold Spring Harbor Laboratory Press -

International audience. Melanoma cells can enter the process of senescence, but whether they express a secretory phenotype, as reported for other cells, is undetermined. This is of paramount importance, because this secretome can alter the tumor microenvironment and the response to chemotherapeutic drugs. More generally, the molecular events involved in formation of the senescent-associated secretome have yet to be determined. We reveal here that melanoma cells experiencing senescence in response to diverse stimuli, including anti-melanoma drugs, produce an inflammatory secretory profile, where the chemokine ligand-2 (CCL2) acts as a critical effector. Thus, we reveal how senescence induction might be involved in therapeutic failure in melanoma. We further provide a molecular relationship between senescence induction and secretome formation by revealing that the poly(ADP-ribose) polymerase-1 (PARP-1)/nuclear factor-κB (NF-κB) signaling cascade, activated during senescence, drives the formation of a secretome endowed with protumoral and prometastatic properties. Our findings also point to the existence of the PARP-1 and NF-κB-associated secretome, termed the PNAS, in nonmelanoma cells. Most importantly, inhibition of PARP-1 or NF-κB prevents the proinvasive properties of the secretome. Collectively, identification of the PARP-1/NF-κB axis in secretome formation opens new avenues for therapeutic intervention against cancers.

Consulter en ligne

Suggestions

Du même auteur

Involvement of FKHRL1 in melanoma cell survival and death

Archive ouverte | Hilmi, C. | CCSD

International audience. Melanoma is a highly aggressive tumour characterized by a strong resistance to apoptotic stimuli that give rise to a selective advantage for tumour progression and metastasis formation. There...

Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma

Archive ouverte | Bertolotto, C. | CCSD

International audience

Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner

Archive ouverte | Cerezo, M. | CCSD

International audience. Metformin was reported to inhibit the proliferation of many cancer cells, including melanoma cells. In this report, we investigated the effect of metformin on melanoma invasion and metastasis...

Chargement des enrichissements...